Compositions and Methods for Inhibition of the Jak Pathway
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 61/368,570, filed Jul 28, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US RE47,396 | Compositions and Methods for Inhibition of the Jak Pathway In force · Low confidence | Rigel Pharmaceuticals, Inc. | In force | Low confidence | ||
| US 8,343,954 | Compositions and Methods for Inhibition of the Jak Pathway In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,479,783 | Compositions and Methods for Inhibition of the Jak Pathway In force · Medium confidence | Rigel Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 11,174,251 | Compositions and Methods for Inhibition of the Jak Pathway In force · Medium confidence | Rigel Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,067,925 | Compositions and Methods for Inhibition of the Jak Pathway Surrendered on reissue May 21, 2019 Low confidence | Rigel Pharmaceuticals, Inc. | Surrendered on reissue May 21, 2019 | Low confidence | ||
| US 9,611,260 | Compositions and Methods for Inhibition of the Jak Pathway Lapsed Apr 4, 2025 on the fee record Medium confidence | Rigel Pharmaceuticals, Inc. | Lapsed Apr 4, 2025 on the fee record | Medium confidence | ||
| US 9,920,041 | Compositions and Methods for Inhibition of the Jak Pathway Lapsed Mar 20, 2026 on the fee record Medium confidence | Rigel Pharmaceuticals, Inc. | Lapsed Mar 20, 2026 on the fee record | Medium confidence | ||
| Application 17/494,370 | Compositions and Methods for Inhibition of the Jak Pathway Abandoned Abandoned Mar 7, 2025 | Rigel Pharmaceuticals, Inc. | Abandoned | Abandoned Mar 7, 2025 |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Rigel Pharmaceuticals, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.